Clinical Trials

Find a Clinical Trial

Enrolling Trials

81-90  of  169
►
CIRB, MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Mutations
Adult
qatest
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, Molecular Analysis for Therapy Choice (MATCH): EAY131-L: MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
Mutations
Adult
This subprotocol (EAY131-L) should be used in conjunction with the MATCH Master Protocol (EAY131)
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, Molecular Analysis for Therapy Choice (MATCH): EAY131-M: MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Mutations
Adult
This subprotocol (EAY131-M) should be used in conjunction with the MATCH Master Protocol (EAY131).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutation
Mutations
Adult
The study objectives are to address the need for accurate and rapid Borrelia detection and identification, the Sponsor intends to extend the utility of its direct-from-specimen molecular diagnostic platform, RaPID (Resistance and Pathogen IDentification), to facilitate ultra-sensitive, direct detection of Borrelia from whole-blood. RaPID, leverages proprietary duplex DNA invading artificial nucleic acids and provides direct-from-sample results in roughly 3 hours. The objective of this study is to provide samples sufficient for research and development needs for HelixBind's RaPID/LD assay.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Mutations
Adult
test objective
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
Mutations
Adult
This subprotocol (EAY131-Z1E) should be used in conjunction with the MATCH Master Protocol (EAY131).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Mutations
Adult
MATCH Treatment Subprotocol Z1K
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations
Mutations
Adult
MATCH Treatment Subprotocol Z1L
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
Functional Magnetic Resonance Imaging (fMRI) of the Brain in Individuals with Bardet-Biedl Syndrome: focus on receptive and expressive language center
Nephrology
Child
The purpose of this study is to examine possible anatomic differences in brain receptive and expressive language centers in Bardet-Biedl syndrome (BBS) compared to normal age and gender matched monolingual controls using functional magnetic resonance imaging 9fMARI).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
Development and Implementation of a Pilot Universal Newborn Screening Program for Congenital Cytomegalorvirus Infection (cCMV) across Marshfield Clini
Development and Implementation of a Pilot Universal Newborn Screening Program for Congenital Cytomegalorvirus Infection (cCMV) across Marshfield Clinic Health System
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449